Article Details
Retrieved on: 2018-01-29 13:37:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>Inozyme plans to use the funding to bring the preclinical therapy into human testing and ultimately the clinic in two to three years. Over the span of 18 months, the startup has gotten funding from Longitude Capital, <b>New Enterprise Associates</b>, Novo Ventures and Sanofi Ventures. “We'd like to get this drug ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here